Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
ZIANA® (clindamycin phosphate 1.2% and tretinoin 0.025%) gel, marketed by Medicis, The
Dermatology Company®, is a safe and effective topical therapy used for the treatment of acne
vulgaris. Actavis Mid-Atlantic LLC has developed a generic formulation of clindamycin
phosphate (1.2%) and tretinoin (0.025%) topical gel and the current study is designed to
evaluate the bioequivalence of this formulation to ZIANA®.
Phase:
N/A
Details
Lead Sponsor:
Actavis Mid-Atlantic LLC
Treatments:
Clindamycin Clindamycin palmitate Clindamycin phosphate Clindamycin, tretinoin drug combination Tretinoin